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Abstract
Background The use of remanufactured single-use devices (SUDs), including cardiac electrophysiology catheters, has become
established in the USA and other health care systems but without much published scientific evaluation on the relative safety or
efficacy of these devices. In the United Kingdom (UK), the use of remanufactured SUDs has not been routine. We performed a
structured evaluation of the safety and efficacy of a remanufactured circular mapping catheter (Stryker® remanufactured Lasso
NAV 2515) during its introduction in our centre.
Methods We prospectively evaluated the performance of a remanufactured circular mapping catheter in 100 consecutive patients
undergoing an AF ablation. Operator feedback was obtained, assessing the device appearance, ease of use and function. As an
indirect measurement of efficacy, acute procedure metrics were compared to those in 100 propensity-matched cases performed by
the same operators using a new device. Cost savings were calculated.
Results No complication occurred in association with the remanufactured device. There was one reported failure of device
malfunction—the flexion-extension mechanism of a remanufactured catheter and none in the matched-control group. There
was satisfactory communication with the electro-anatomic mapping system. Ease of use of the remanufactured catheter was
reported to be similar to a newlymanufactured device. Procedural duration was similar with remanufactured devices andmatched
controls. With 100 cases using the remanufactured device, cost savings amounted to £30,444.
Conclusions The use of remanufactured circular mapping catheters is safe, efficient and reliable. Widespread use of
remanufactured SUDs offers the possibility of significant economic benefit.
Keywords Remanufacturing . Cardiac electrophysiology catheters . Circular mapping catheters . Infection risk . Sterilisation .
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1 Background
The use of remanufactured single-use devices (SUDs),
including electrophysiology (EP) catheters, has been
established for decades in the USA. [1] Re-use of cathe-
ters was widespread in the early years of electrophysiolo-
gy, but this generally involved just rudimentary checking,
cleaning and re-sterilisation of the catheter within the
healthcare institution, a practice that declined in response
to the labelling of devices as ‘single-use only’. Modern
remanufacturing is performed on an industrial scale with
rigorous adherence to defined protocols, producing a
remanufactured device which has been performance-
tested and shown to meet the original equipment manu-
facturer (OEM) requirements. The verifiable elimination
of infective agents is central to the process.
The financial burden on healthcare systems is ever increas-
ing and the cost of running a cardiac EP laboratory is high.
The prevalence of atrial fibrillation in Europe is estimated to
be over 6 million, and this is likely to increase over the on-
coming decades based on recent population studies [2]; a sig-
nificant proportion of these patients will go on to require cath-
eter ablation including repeat procedures. The incentive for
investigating the integration of remanufactured cardiac EP
catheters as part of routine use is to provide a sustainable
approach to cost reduction in the cardiac EP laboratory.
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The remanufactured device is treated as a completely dif-
ferent product in the device industry; the responsibilities re-
main specific to the remanufacturing company and
remanufacturing industry regulations, completely separate to
the original device and the manufacturer. Despite this and the
fact that remanufacturing has the capacity to alter the charac-
teristics of a device, no remanufactured SUD has been the
subject of a structured evaluation published in the scientific
literature. Over the many years of widespread use of
remanufactured SUDs in everyday practice in the USA, there
have been no major adverse events attributable to the
remanufacturing process; conversely, there is little published
scientific evidence to confirm the safety of this approach and
none specific to EP catheters [1, 3–7].
The Lasso® mapping catheter (Carto® Lasso® 2515
Eco, Biosense-Webster® Johnson&Johnson, Diamond
Bar, USA) is a specialised device with a tip that is fashioned
into a circular geometry (Fig. 1). The circular component
can be adjusted in its diameter. The shaft can be flexed or
extended. In a typical procedure, the Lasso® catheter is
expected to be adjusted frequently and exposed to torque
and linear stress, cardiac movement and other catheter
movement for a duration of over 2 h. The purpose of this
study was to prospectively evaluate the safety and efficacy
of a remanufactured version of the Lasso® 2515 eco
Variable Catheter during AF ablation procedures compared
to propensity matched control procedures performed using
the newly manufactured version of the catheter.
2 Methods
We prospectively studied 100 consecutive patients undergo-
ing elective AF ablation using a remanufactured circular map-
ping catheter (Stryker®, Michigan, USA), a remanufactured
version of the 22-pole model of the Lasso® 2515 eco Variable
Catheter (Biosense-Webster®), with an electro-anatomic sys-
tem (Carto®, Biosense-Webster®). All patients were
propensity-matched to cases performed using a previously
unused circular mapping catheter of the same model (the
‘first-use’ group) selected from a database of 806 AF ablations
performed over the previous 4 years.
A record was made of any catheter-associated problem that
occurred, and a structured interview was held with the opera-
tor immediately after the procedure to evaluate the perfor-
mance of the catheter. After the procedure, the catheter was
inspected for any defect in the electrodes or the insulation, for
any deformation of its curve, or any malfunction in its deflec-
tion mechanism.
The parameters assessed were catheter-related complica-
tions during or after the procedure, ease of handling the
catheter during the case, failure of electrodes to record elec-
trograms or to stimulate appropriately, failure of communi-
cation with the electro-anatomic mapping system, and phys-
ical defect or deformation of the catheter on inspection after
use. Indirect markers of catheter function were also mea-
sured including procedure duration and fluoroscopy dura-
tion. Complications that did not have any likely relationship
to the catheter were also recorded up until the point of dis-
charge from hospital, including any major adverse
cardiovascular/cerebrovascular events (MACCE), vascular
injury, or cardiac tamponade.
Patients were followed up at 3 months after the proce-
dure. Medical records were reviewed for evidence of com-
plications of the procedure occurring in the period within
3 months after ablation, and for any pyrexial or infective
illness reported in this period. Total cost savings to the de-
partment was calculated.
2.1 Statistics
To estimate the propensity score, we used logistic regres-
sion including the following co-variates: age, gender,
performing operator and procedural complexity character-
istics. Matching was performed with the nearest neighbour
method using a 1:1 ratio (R extension pack - R version
2.15.0). Analysis was conducted between the matched co-
horts. The level of significance was set to 0.05. Analysis
was performed with IBM SPSS statistical software (version
22.0; IBM SPSS Statistics, NY, USA).
Fig. 1 Photograph of the
Stryker® remanufactured Lasso
NAV 2515 circular mapping
catheter (left) and the original
device, Lasso® (right). Other than
the markings on the handle of the
device, we have not been able to
identify any difference on careful
inspection of each
remanufactured device compared
to the newly manufactured
version
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3 Results
The study patients (remanufactured) and the control (first use)
population were well matched for demographic and procedur-
al characteristics (Fig. 2; Table 1). All of the Stryker®
remanufactured catheters used were at the first reuse cycle
(the NAV version can only be reused once). No complication
occurred in either group that could be attributed to the perfor-
mance of the circular mapping catheter. Of other complica-
tions, there was one case of cardiac tamponade in the
matched-control group.
There was only one confirmed case of failure of a
remanufactured catheter. The flexion-extension mechanism
completely failed mid-procedure, having performed normally
until that point. The catheter was removed without difficulty
and the procedure completed with a replacement catheter.
Assessment of the catheter confirmed the failure of the flexion
mechanism due to the contraction puller wire coming off the
ferrule. In one other case, the operator returned a
remanufactured catheter for retesting after the procedure due
to a perceived limitation in flexion, but on retesting against
OEM standards, the device was found to function normally.
There was no negative feedback about the mechanical func-
tion of the remanufactured catheter in other cases. There were
no instances of physical defects or deformation of the catheter
upon inspection after use. The quality of electrograms and the
communication between the catheter and the electro-anatomic
mapping system and stimulator were satisfactory in all cases.
There was no report of sub-optimal performance among the
100 matched control cases.
The procedure duration was similar in the study group and
matched controls (‘remanufactured’ 178.9 ± 51.3 versus first
use 189.5 ± 55.3, P = 0.16) (Table 2). The first-use group had
higher overall fluoroscopy duration compared to the
remanufactured group (21.5 ± 13.5 versus 11.8 ± 9.6 min, re-
spectively, P < 0.0001).
Comparing the list prices, the remanufactured circular
mapping catheter was 45% cheaper than the newly
manufactured version. The cost savings to our department
arising from these 100 cases amounted to £30,444.
Fig. 2 Comparative graphs of remanufactured and first-use circular
mapping catheters. a Patient age (years). b Procedure duration (min).
Graph a is to demonstrate adequate propensity matching, which apart
from age also includes patient gender and operator. Graph b shows no
significant overall difference in procedure times in the study or matched
controls
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4 Discussion
St. George’s Hospital is the first UK centre to have ‘real-
world’ experience on remanufactured electrophysiology cath-
eters. We have tested the use of the remanufactured Lasso
NAV 2515 circular mapping catheters prospectively and
found it to be as safe and as efficient as a newly manufactured
device. There was no acute complication among the 100 cases
s tudied . This s tudy suppor ts the in tegra t ion of
remanufacturing into UK and EU healthcare systems as a
sustainable approach to cost-effectiveness that also maintains
safety and efficacy standards for our patients.
4.1 Mechanical performance
A deformed or broken circular mapping catheter could be a
dangerous instrument. Deformation of the circular geometry
could cause the tip to protrude and potentially lacerate the wall
of the left atrium. Deformation of the shaft could increase the
risk of catheter entrapment in the mitral apparatus; defects in
the insulation of the catheter could provide a stimulus to
thrombosis and increase the risk of systemic embolisation.
Any issues associated with catheter malfunction would be
expected to manifest during or immediately after the
procedure, or would be revealed by inspection of the catheter
at the end of the procedure. The absence of major problems
observed therefore assures us that the remanufacturing process
is robust in limiting the potential for mechanical defects.
The observed 1% catheter failure rate among the
remanufactured catheters was not replicated in the matched
control cases but is in keeping with the long-term experience
of our unit. We have recorded five instances of confirmed fail-
ure of first-use circular mapping catheters over 5 years, during
which period over 800 such catheters were used. There were a
range of faults including damaged connections, puller wire
coming off the ferrule and internal failure of the sensor.
Procedure duration times were similar in the remanufactured
and first-use groups, supporting the impression that the
remanufactured catheters functioned to the standard expected
of an original device. The catheters were used in a wide mix of
AF ablation cases, ranging from PVI to more complex and
lengthy procedures, some lasting over 4 h. Only fluoroscopy
times differed between the remanufactured and first-use groups.
The control cases were from a historic database, and we believe
that this difference reflects the progressive decline in reliance on
fluoroscopy seen in our unit in recent years.
4.2 Validating mechanical performance
of remanufactured SUDs
The remanufactured catheters studied in this series had all
undergone a controlled and structured approach in the cycle
of remanufacturing (Fig. 3). All catheters were tested against
OEM standards on entering the remanufacturing cycle. The
testing involved a number of redundant quality control steps
testing torsion, deflection, joint seal integrity and tensile
strength to verify manoeuvrability, stability and reliability.
Curves were measured against standard templates to assess
the direction, shape and plane of the curve against
predetermined criteria. The circular mapping catheter had to
Table 1 Patient characteristics
Parameters Remanufactured First use
Male (n) 68 68
Female (n) 32 32
Overall average age 67.1± 8.5 SD 65.8± 9.1 SD
AF subtype (n)
PAF 37 37
Pe-AF 33 33
Redo cases 30 30
Table 2 Procedural
characteristics Parameters Remanufactured First use P value
Procedure duration (min)
(a) PAF 157.9 ± 45.7 SD 164.2 ± 44.7 SD P = 0.55
(b) Pe-AF 208.5 ± 49.1 SD 226.8 ± 59.3 SD P = 0.18
(c) Redo cases 172.4 ± 46 SD 179.7 ± 39.6 SD P = 0.51
Fluoroscopy duration (min) 11.8 ± 9.60 SD 21.5 ± 13.5 SD P < 0.0001
PVI only (n) 37 37 N/A
PVI+ (n) 51 51 N/A
Other (CFAE, linear) (n) 12 12 N/A
Patient major complication (n) 0 0 N/A
Patient minor complication (n) 0 0 N/A
Mapping catheter failure (n) 1 0 N/A
Other catheter failure (n) 0 0 N/A
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flex to a ‘D curve’ (Fig. 4). Over- or under-flexion or deflec-
tion from the plane of flexion would not have met OEM stan-
dards and would therefore have been deemed unacceptable.
The tests were completed three times for each catheter. Each
remanufactured device has a unique code on the device handle
and on the packaging to track its progress through the system,
and if appropriate, the device details can be traced back to its
origin and to determine its reuse cycle (first reuse or second
reuse). This will also enable any device-related issues to be fed
back to the company.
4.3 Infective agents
The reuse of medical devices and surgical equipment carries a
small but important risk of transmission of infective agents.
Prions are a particular concern in the UK, which was the
epicentre of the outbreak of variant Creutzfeldt Jakob disease
from 1996 onwards and still accounts for a large majority of
cases worldwide [8]. The medical literature includes more
than 400 reported cases of iatrogenic Creutzfeldt Jakob dis-
ease transmission, mostly through the use of pituitary extracts
and dura mater grafts, but also from neurosurgical instruments
and blood transfusions [9]. Prions are resistant to proteolytic
enzymes and remain pathogenic even after long periods of
time and exposure to high heat of up to 200° [10].
Viruses are also of concern, particularly the widespread
hepatitis C virus (HCV). Iatrogenic hepatitis C transmission
is not common, and when it occurs is usually from a HCV-
infected operator [11]. Druce et al. performed experimental
studies assessing the efficacy of various sterilisation proto-
cols in eradicating hepatitis and Coxsackie viruses from
used cardiac electrophysiology catheters [12]. They found
that blood borne viruses could be eliminated by exposure to
ethylene oxide, an alkylating chemical which effectively
inactivates DNA of microorganisms; virus nucleic acid
persisted in catheters that had been simply washed in deter-
gent or exposed to enzyme cleaners.
The remanufacturing of the catheters involved in the
current study included a validated protocol to eliminate
infective agents, involving thorough cleaning and expo-
sure to the ethylene oxide. Ethylene oxide has been
shown to be compatible with the polyurethane that
forms most of the external surface of the catheter, and
does not affect its appearance or physical characteristics.
Other forms of sterilisation may induce a brittle or
‘yellowing’ quality to plastic polymers and can create
additional friction between interacting catheter surfaces.
Although no instance of transmission of infection by an
electrophysiological catheter has been reported, it must
be noted that it is notoriously difficult to fully assess
prion transmission as prion-related conditions may re-
main indolent for decades.
Fig. 3 The cycle of
remanufacturing single-use
devices (SUDs)
Fig. 4 Original equipment manufacturer (OEM) tests against a template.
The BD curve^ of the circular mapping catheter is tested; the annotated
green line measures the angle created by the shaft of the catheter. The
orange line represents the angle of deflection from the catheter tip and has
to be greater than 0 to pass the test
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4.4 Regulations governing remanufacturing of SUDs
In the USA, the Food and Drug Administration (FDA) has
reviewed and officially reported on the remanufacturing in-
dustry. They have found no evidence that the use of
remanufactured devices increased the risk to health, with over
two decades of experience [1]. However, there is a lack of
peer-reviewed studies into the remanufactured devices and
so we are still without comprehensive assessment into the
relative safety of these devices. FDA data-collection method-
ology has recently become more comprehensive, and this will
probably yield clearer information on the performance and
safety of reprocessed devices in the future.
The Medicines and Healthcare products Regulatory
Agency (MHRA) permits the practice of remanufacturing
SUDs within strict guidelines [13–16]. There should be ad-
herence to the medical devices directive and a CE mark for
each product. The remanufacturing company must transfer the
devices in a closed loop system between themselves and the
healthcare provider. Guidelines are in place to monitor decon-
tamination and sterilisation processes, as well as adverse event
reporting via the European Union (EU) Medical Devices
Vigilance System [17, 18].
4.5 Other reprocessed medical devices
Other cardiac electrophysiology catheters are available as
remanufactured versions, including decapolar coronary sinus
catheters, but the same processes could be applied to many
other models. We began our experience of remanufactured
catheters with the circular mapping catheter as it is particularly
intricate in its construction and is particularly subject to stress
during routine use. If this catheter can withstand the
remanufacturing process in good condition and survive a sec-
ond procedure, we believe that other catheters are likely to
perform at least equally well. Other medical devices available
in the remanufactured form include devices used in general
and laparoscopic surgery, for example endoscopic trocars and
balloon inflation devices.
4.6 Cost implications
Based on list prices, we have calculated the cost savings to our
department arising from these 100 cases at £30,444. An esti-
mated 5000–10,000 ablations requiring the use of a circular
mapping catheter are performed annually in the UK [19, 20],
implying the potential for an annual saving of £1,700,000 if
half of these were switched to the remanufactured version.
The overall potential cost savings from all reprocessed
SUDs is estimated at £17 million per annum in the UK alone
with scope to increase [17]. In 2017, the total cost savings to
the US healthcare system from the remanufacturing of SUDs
was estimated to exceed $326,000,000 [21]. Published sav-
ings from individual centres were also significant: WakeMed
and Duke were able to save $750,000 and $839,000, respec-
tively, in the years 2013–2014.
Integration of remanufactured devices into everyday clini-
cal practice would be a sustainable cost reduction strategy to
the cardiac EP department; the safety of this practice should be
accounted for by careful external regulation alongside regular
internal auditing by each individual department. This cost re-
duction method may enable continued expansion of AF abla-
tion services and so meet the ever increasing demand for cath-
eter ablation treatment.
The cost benefit arising from the remanufacturing of SUDs
is of even greater importance in less wealthy nations. AF is a
world-wide problem, but AF ablation is disproportionately
available to richer populations; others must endure the disabil-
ity of the arrhythmia or the dangers associated with antiar-
rhythmic medications. Reducing the cost per procedure
should permit the treatment to more of the population in need.
5 Conclusion
The remanufactured circular mapping catheter proved to be
safe and efficient with no adverse events and with satisfactory
catheter performance. The incorporation of remanufactured
SUDs into standard practice in a carefully regulated system
could provide significant economic benefit without
compromising safety.
6 Limitations
Because of the relatively small study population and short
duration of follow-up, our study cannot exclude the possibility
of transmission of infective agents; further study over a longer
duration would be required to establish absolute safety from
transmission of infection. The study was not ‘blinded’ so op-
erator bias cannot be excluded.
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